MedTrace Logo

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

NCT07467447 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-03-12

No results posted yet for this study

Summary

Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.

Conditions

Interventions

DRUG

Retatrutide (LY3437943)

subcutaneous injection, once weekly (dose per assigned arm).

DRUG

Placebo

subcutaneous injection, once weekly (schedule matched to an active arm).

BEHAVIORAL

Standardized diet and physical activity counseling throughout the study.

Standardized diet and physical activity counseling throughout the study.

Sponsors & Collaborators

  • Hudson Biotech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-15
Primary Completion
2027-03-14
Completion
2028-02-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07467447 on ClinicalTrials.gov